The clinical efficacy and safety of certolizumab pegol (CZP) in the treatment of rheumatoid arthritis: focus on long-term use, patient considerations and the impact on quality of life
Roy FleischmannMetroplex Clinical Research Center, Dallas, Texas, USAAbstract: Rheumatoid arthritis can cause chronic pain, disability, fatigue and loss of productivity both in the workplace and at home. Fatigue, not joint pain, swelling or that there may be radiographic damage, is frequently mentio...
Guardado en:
Autor principal: | Roy Fleischmann |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2009
|
Materias: | |
Acceso en línea: | https://doaj.org/article/3615454d2ee6495c8f86318a2856b336 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Certolizumab in the long-term treatment of rheumatoid arthritis
por: Scott DL, et al.
Publicado: (2011) -
Spotlight on certolizumab pegol in the treatment of axial spondyloarthritis: efficacy, safety and place in therapy
por: Marin J, et al.
Publicado: (2018) -
An evidence-based review of certolizumab pegol in the treatment of active psoriatic arthritis: place in therapy
por: Acosta-Felquer ML, et al.
Publicado: (2016) -
Efficacy, safety, and tolerability of abatacept in the management of rheumatoid arthritis
por: Joseph R Lutt
Publicado: (2009) -
Critical appraisal of efficacy and safety of abatacept in the treatment of refractory rheumatoid arthritis
por: Augustine JM, et al.
Publicado: (2012)